Literature DB >> 23630276

Loss of function of Ribonuclease T2, an ancient and phylogenetically conserved RNase, plays a crucial role in ovarian tumorigenesis.

Francesco Acquati1, Marta Lualdi, Sabrina Bertilaccio, Laura Monti, Giovanna Turconi, Marco Fabbri, Annalisa Grimaldi, Achille Anselmo, Antonio Inforzato, Angelo Collotta, Laura Cimetti, Cristina Riva, Laura Gribaldo, Paolo Ghia, Roberto Taramelli.   

Abstract

In recent years, the role played by the stromal microenvironment has been given growing attention in order to achieve a full understanding of cancer initiation and progression. Because cancer is a tissue-based disease, the integrity of tissue architecture is a major constraint toward cancer growth. Indeed, a large contribution of the natural resistance to cancer stems from stromal microenvironment components, the dysregulation of which can facilitate cancer occurrence. For instance, recent experimental evidence has highlighted the involvement of stromal cells in ovarian carcinogenesis, as epitomized by ovarian xenografts obtained by a double KO of the murine Dicer and Pten genes. Likewise, we reported the role of an ancient extracellular RNase, called Ribonuclease T2 (RNASET2), within the ovarian stromal microenvironment. Indeed, hyperexpression of RNASET2 is able to control tumorigenesis by recruiting macrophages (mostly of the anticancer M1 subtype) at the tumor sites. We present biological data obtained by RNASET2 silencing in the poorly tumorigenetic and highly RNASET2-expressing human OVCAR3 cell line. RNASET2 knockdown was shown to stimulate in vivo tumor growth early after microinjection of OVCAR3 cells in nude mice. Moreover, we have investigated by molecular profiling the in vivo expression signature of human and mouse cell xenografts and disclosed the activation of pathways related to activation of the innate immune response and modulation of ECM components. Finally, we provide evidence for a role of RNASET2 in triggering an in vitro chemotactic response in macrophages. These results further highlight the critical role played by the microenvironment in RNASET2-mediated ovarian tumor suppression, which could eventually contribute to better clarify the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23630276      PMCID: PMC3657777          DOI: 10.1073/pnas.1222079110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

Review 1.  The microenvironment of the tumour-host interface.

Authors:  L A Liotta; E C Kohn
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

2.  Tumor and metastasis suppression by the human RNASET2 gene.

Authors:  Francesco Acquati; Laura Possati; Luigi Ferrante; Paola Campomenosi; Simona Talevi; Silvana Bardelli; Chiara Margiotta; Antonella Russo; Elisabetta Bortoletto; Romina Rocchetti; Roberta Calza; Raffaella Cinquetti; Laura Monti; Silvia Salis; Giuseppe Barbanti-Brodano; Roberto Taramelli
Journal:  Int J Oncol       Date:  2005-05       Impact factor: 5.650

3.  RNASET2--an autoantigen in anaplastic large cell lymphoma identified by protein array analysis.

Authors:  Suketu Patel; Hong Chen; Laura Monti; Edith Gould; Eugenia Haralambieva; Jasmin Schmid; David Toomey; Wilhelm Woessmann; Giovanna Roncador; Chris S R Hatton; Amanda P Liggins; Roberto Taramelli; Alison H Banham; Francesco Acquati; Derek Murphy; Karen Pulford
Journal:  J Proteomics       Date:  2012-06-23       Impact factor: 4.044

Review 4.  Precursor lesions of ovarian epithelial malignancy.

Authors:  K M Feeley; M Wells
Journal:  Histopathology       Date:  2001-02       Impact factor: 5.087

Review 5.  The molecular biology of leukocyte chemoattractant receptors.

Authors:  P M Murphy
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

Review 6.  Why do we not all die of cancer at an early age?

Authors:  George Klein; Stefan Imreh; Eugene R Zabarovsky
Journal:  Adv Cancer Res       Date:  2007       Impact factor: 6.242

7.  Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer.

Authors:  Tanya J Shaw; Mary K Senterman; Kerri Dawson; Colleen A Crane; Barbara C Vanderhyden
Journal:  Mol Ther       Date:  2004-12       Impact factor: 11.454

8.  Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes.

Authors:  N Auersperg; S L Maines-Bandiera; H G Dyck; P A Kruk
Journal:  Lab Invest       Date:  1994-10       Impact factor: 5.662

9.  Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria.

Authors:  Frank A W Verreck; Tjitske de Boer; Dennis M L Langenberg; Marieke A Hoeve; Matthijs Kramer; Elena Vaisberg; Robert Kastelein; Arend Kolk; René de Waal-Malefyt; Tom H M Ottenhoff
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-19       Impact factor: 11.205

10.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

View more
  18 in total

1.  New Strategies for Expression and Purification of Recombinant Human RNASET2 Protein in Pichia pastoris.

Authors:  Marta Lualdi; Edoardo Pedrini; Francesca Petroni; Johnny Näsman; Christer Lindqvist; Debora Scaldaferri; Roberto Taramelli; Antonio Inforzato; Francesco Acquati
Journal:  Mol Biotechnol       Date:  2015-06       Impact factor: 2.695

Review 2.  AIF-1 and RNASET2 Play Complementary Roles in the Innate Immune Response of Medicinal Leech.

Authors:  Nicolò Baranzini; Laura Monti; Marta Vanotti; Viviana T Orlandi; Fabrizio Bolognese; Debora Scaldaferri; Rossana Girardello; Gianluca Tettamanti; Magda de Eguileor; Jacopo Vizioli; Roberto Taramelli; Francesco Acquati; Annalisa Grimaldi
Journal:  J Innate Immun       Date:  2018-10-26       Impact factor: 7.349

3.  Association of Ribonuclease T2 Gene Polymorphisms With Decreased Expression and Clinical Characteristics of Severity in Crohn's Disease.

Authors:  Rivkah Gonsky; Phillip Fleshner; Richard L Deem; Eva Biener-Ramanujan; Dalin Li; Alka A Potdar; Janine Bilsborough; Shaohong Yang; Dermot P B McGovern; Stephan R Targan
Journal:  Gastroenterology       Date:  2017-04-09       Impact factor: 33.883

4.  Pleiotropic modes of action in tumor cells of RNASET2, an evolutionary highly conserved extracellular RNase.

Authors:  Marta Lualdi; Edoardo Pedrini; Katia Rea; Laura Monti; Debora Scaldaferri; Marzia Gariboldi; Annalisa Camporeale; Paolo Ghia; Elena Monti; Antonella Tomassetti; Francesco Acquati; Roberto Taramelli
Journal:  Oncotarget       Date:  2015-04-10

5.  An ribonuclease T2 family protein modulates Acinetobacter baumannii abiotic surface colonization.

Authors:  Anna C Jacobs; Catlyn E Blanchard; Seana C Catherman; Paul M Dunman; Yoshihiko Murata
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

Review 6.  The role of the tumor stroma in ovarian cancer.

Authors:  Ben Davidson; Claes G Trope; Reuven Reich
Journal:  Front Oncol       Date:  2014-05-13       Impact factor: 6.244

7.  Human RNASET2 derivatives as potential anti-angiogenic agents: actin binding sequence identification and characterization.

Authors:  Liron Nesiel-Nuttman; Shani Doron; Betty Schwartz; Oded Shoseyov
Journal:  Oncoscience       Date:  2014-11-26

8.  Expression, Location, Clinical Implication, and Bioinformatics Analysis of RNASET2 in Gastric Adenocarcinoma.

Authors:  Zhi Zeng; Xu Zhang; Dan Li; Jin Li; Jingping Yuan; Lijuan Gu; Xiaoxing Xiong
Journal:  Front Oncol       Date:  2020-05-22       Impact factor: 6.244

Review 9.  Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells.

Authors:  Francesca Roggiani; Delia Mezzanzanica; Katia Rea; Antonella Tomassetti
Journal:  Int J Mol Sci       Date:  2016-08-23       Impact factor: 5.923

Review 10.  Immune Modulation by Human Secreted RNases at the Extracellular Space.

Authors:  Lu Lu; Jiarui Li; Mohammed Moussaoui; Ester Boix
Journal:  Front Immunol       Date:  2018-05-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.